[go: up one dir, main page]

BR112017018964A2 - uso de plinabulin e métodos para tratar tumor cerebral - Google Patents

uso de plinabulin e métodos para tratar tumor cerebral

Info

Publication number
BR112017018964A2
BR112017018964A2 BR112017018964A BR112017018964A BR112017018964A2 BR 112017018964 A2 BR112017018964 A2 BR 112017018964A2 BR 112017018964 A BR112017018964 A BR 112017018964A BR 112017018964 A BR112017018964 A BR 112017018964A BR 112017018964 A2 BR112017018964 A2 BR 112017018964A2
Authority
BR
Brazil
Prior art keywords
plinabulin
methods
brain tumor
treat brain
treat
Prior art date
Application number
BR112017018964A
Other languages
English (en)
Inventor
Huang Lan
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56880412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017018964(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of BR112017018964A2 publication Critical patent/BR112017018964A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

são divulgados aqui métodos de tratamento de um tumor cerebral através da administração de plinabulin. algumas modalidades referem-se ao tratamento de glioblastoma multiforme através da administração de plinabulin.
BR112017018964A 2015-03-06 2016-03-02 uso de plinabulin e métodos para tratar tumor cerebral BR112017018964A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129623P 2015-03-06 2015-03-06
US201562249807P 2015-11-02 2015-11-02
PCT/US2016/020396 WO2016144636A1 (en) 2015-03-06 2016-03-02 Method of treating a brain tumor

Publications (1)

Publication Number Publication Date
BR112017018964A2 true BR112017018964A2 (pt) 2018-05-22

Family

ID=56880412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018964A BR112017018964A2 (pt) 2015-03-06 2016-03-02 uso de plinabulin e métodos para tratar tumor cerebral

Country Status (17)

Country Link
US (2) US10076518B2 (pt)
EP (1) EP3265091A4 (pt)
JP (2) JP6904570B2 (pt)
KR (1) KR102623404B1 (pt)
CN (1) CN107530340B (pt)
AU (2) AU2016229295B2 (pt)
BR (1) BR112017018964A2 (pt)
CA (1) CA2978679A1 (pt)
CL (1) CL2017002242A1 (pt)
HK (2) HK1249051A1 (pt)
IL (1) IL254262A0 (pt)
MX (1) MX385914B (pt)
MY (1) MY194341A (pt)
RU (1) RU2728796C2 (pt)
SG (1) SG11201707128TA (pt)
WO (1) WO2016144636A1 (pt)
ZA (1) ZA201706035B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1250008A1 (zh) 2015-03-06 2018-11-23 万春药业公司 治療與ras突變相關的癌症的方法
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) * 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
WO2021150109A1 (en) * 2020-01-22 2021-07-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Abt-751 and ionizing radiation
AU2021251277A1 (en) * 2020-04-10 2022-11-10 Lantern Pharma Inc. Hydroxyureamethyl-acylfulvene for treating brain cancer or CNS cancer
MX2023008106A (es) * 2021-01-08 2023-09-21 Lantern Pharma Inc Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno.
US20240197723A1 (en) * 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (pt) 1973-05-11 1975-01-30
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPS6411523A (en) 1987-07-06 1989-01-17 Kawashima Tekko Kk Dish feeder in tableware washing machine
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2119996T3 (es) 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
AU747987B2 (en) 1998-01-29 2002-05-30 Aventis Pharmaceuticals Inc. Method for preparing an N-((aliphatic or aromatic)carbonyl)-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
BRPI0017067B8 (pt) 2000-01-18 2021-05-25 Beyondspring Pharmaceuticals Inc inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
BR0110745A (pt) 2000-05-09 2003-12-30 Adpharma Inc Compostos de piperazinadiona
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP4616649B2 (ja) 2002-08-02 2011-01-19 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
EP1711487A1 (en) * 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
JP2009523813A (ja) * 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011019630A2 (en) * 2009-08-10 2011-02-17 Board Of Regents, The University Of Texas System Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) * 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
SMT201800294T1 (it) 2011-04-20 2018-07-17 Medimmune Llc Anticorpi e altre molecole che legano b7-h1 e pd-1
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) * 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
NZ719049A (en) * 2013-10-11 2020-06-26 Beyondspring Inc Cancer treatment with combination of plinabulin and taxane
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3256130A4 (en) 2015-02-12 2018-08-01 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
HK1250008A1 (zh) 2015-03-06 2018-11-23 万春药业公司 治療與ras突變相關的癌症的方法
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
WO2018169887A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Also Published As

Publication number Publication date
RU2017131448A3 (pt) 2019-08-20
WO2016144636A1 (en) 2016-09-15
MY194341A (en) 2022-11-29
CN107530340B (zh) 2021-06-08
KR102623404B1 (ko) 2024-01-11
AU2021254549A1 (en) 2021-11-18
MX2017011375A (es) 2018-01-23
JP6904570B2 (ja) 2021-07-21
AU2016229295B2 (en) 2021-11-04
AU2021254549B2 (en) 2024-10-24
HK1249051A1 (zh) 2018-10-26
IL254262A0 (en) 2017-10-31
KR20170123642A (ko) 2017-11-08
RU2017131448A (ru) 2019-04-08
US20180042921A1 (en) 2018-02-15
JP2018507245A (ja) 2018-03-15
RU2728796C2 (ru) 2020-07-31
CA2978679A1 (en) 2016-09-15
CN107530340A (zh) 2018-01-02
US20190000841A1 (en) 2019-01-03
EP3265091A1 (en) 2018-01-10
US10076518B2 (en) 2018-09-18
JP2021091695A (ja) 2021-06-17
AU2016229295A1 (en) 2017-09-28
HK1250007A1 (zh) 2018-11-23
ZA201706035B (en) 2019-12-18
SG11201707128TA (en) 2017-09-28
JP7264331B2 (ja) 2023-04-25
EP3265091A4 (en) 2018-08-01
US10357491B2 (en) 2019-07-23
CL2017002242A1 (es) 2018-04-02
MX385914B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017023269A2 (pt) métodos para tratamento de câncer
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
RS64014B1 (sr) Postupci lečenja kancera kože davanjem inhibitora pd-1
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2016025635A3 (en) Combination therapy for treating cancer
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
SV2017005373A (es) Inhibidores de la proteína quinasa c y métodos de su uso
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX376193B (es) Compuestos para tratar el cancer cerebral.
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX373231B (es) Agente anticancerigeno.
WO2016043874A3 (en) Combination therapy for treating cancer
HK1221149A1 (zh) 用於治療前列腺癌的包含二氫吡嗪並-吡嗪化合物和雄激素受體拮抗劑的組合療法
MX2017005064A (es) Metodos para tratar afecciones oculares.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]